Ocular Melanoma clinical trials at UCSF
1 research study open to eligible people
Ocular melanoma is a cancer found in the eye's pigmented cells. UCSF is conducting trials to test drug combinations for treating metastatic uveal melanoma. The research is focused on understanding how these treatments can slow the progression of the disease in patients.
Showing trials for
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
open to eligible people ages 18 years and up
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
San Francisco, California and other locations
Last updated: